Eli Lilly Alzheimer's Drug Faces Tough Road In UK, Price Watchdog NICE Says Donanemab Is Not Cost-Effective
Portfolio Pulse from Vandana Singh
Eli Lilly's Alzheimer's drug, donanemab, has been approved by UK regulators but is not considered cost-effective by NICE, leading to coverage refusal. Despite approval, the drug faces challenges in being adopted due to its high cost relative to benefits.
October 23, 2024 | 6:57 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Eli Lilly's Alzheimer's drug donanemab has been approved in the UK but is not considered cost-effective by NICE, leading to potential challenges in market adoption. This could impact Eli Lilly's stock negatively in the short term.
The approval of donanemab in the UK is a positive development, but the refusal by NICE to cover it due to cost-effectiveness concerns poses a significant hurdle. This could limit the drug's market penetration and affect Eli Lilly's revenue expectations, leading to a potential short-term negative impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100